With more aggressive treatment options, such as pro-protein convertase subtilisin/kexin 9 (PCSK9) inhibitors available, risk stratification may provide the opportunity for a more personalized approach to FH treatment. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.